Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient who is diagnosed as AA and refractory to immunosuppressive therapy~* Platelet ≤ 30,000/μL~Exclusion Criteria:~* Concurrent active infection not adequately responding to appropriate therapy~* HIV positivity~* Bone marrow reticulin grade of \> 1~* Clinically significant cardiac disease~* Arterial or venous thrombosis within the last 1 year before enrollment~* Other cause of thrombocytopenia~* AA with hemolytic predominant paroxysmal nocturnal hemoglobinuria (PNH)~* Uncontrolled diabetes~* Receiving any agent used to treat AA, including antithymocyte globulin (ATG) or ATG + cyclosporine within 6 months before starting study treatment and/or cyclosporine or anabolic hormone within 6 weeks before starting the study treatment~* History of PEG-rHuMGDF, recombinant human thrombopoietin, AMG531, and other thrombopoietin (TPO)-receptor agonist~* Who plans to conduct hematopoietic stem cell transplantation within 1 year

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AMG531 (Dose 1) (Type: EXPERIMENTAL): None
- AMG531 (Dose 2) (Type: EXPERIMENTAL): None
- AMG531 (Dose 3) (Type: EXPERIMENTAL): None
- AMG531 (Dose 4) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).